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Abstract
Objective—We have previously demonstrated robust control of simian/human 
immunodeficiency virus (SHIV1157-ipd3N4) viremia following administration of combination 
antiretroviral therapy (cART) in pigtailed macaques. Here, we sought to determine the safety of 
hematopoietic stem cell transplantation (HSCT) in cART-suppressed and unsuppressed animals.
Design—We compared disease progression in animals challenged with SHIV 100 days post-
transplant (PT), to controls that underwent transplant following SHIV challenge and stable, cART-
dependent viral suppression.
Methods—SHIV viral load, combination antiretroviral therapy (cART) levels, and anti-SHIV 
antibodies were measured longitudinally from plasma/serum from each animal. Flow cytometry 
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was used to assess T-cell subset frequencies in peripheral blood and gastrointestinal tract (GI). 
Deep sequencing was used to identify cART resistance mutations.
Results—In control animals, virus challenge induced transient peak viremia, viral set point, and 
durable suppression by cART. Subsequent HSCT was not associated with adverse events in these 
animals. PT animals were challenged during acute recovery following HSCT, and displayed 
sustained peak viremia and cART resistance. Although PT animals had comparable plasma levels 
of antiretroviral drugs and showed no evidence of enhanced infection of myeloid subsets in the 
periphery, they exhibited a drastic reduction in virus-specific antibody production and decreased 
T-cell counts.
Conclusions—These results suggest that virus challenge prior to complete transplant recovery 
impairs viral control and may promote drug resistance. These findings may also have implications 
for scheduled treatment interruption (STI) studies in patients on cART during post-HSCT 
recovery: premature STI could similarly result in lack of viral control and cART resistance.
Keywords
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Introduction
Hematopoietic stem cell transplantation (HSCT) remains the only clinically exemplified 
route to functional cure/remission of HIV-1 infection [1–3]. The “Berlin Patient”, an HIV+ 
patient diagnosed with acute myeloid leukemia (AML), was transplanted with allogeneic, 
HLA-matched, CCR5Δ32/Δ32 cells in February of 2007, and was removed from his 
combination antiretroviral therapy (cART) regimen concurrently. Following AML relapse 
and a second transplant in March of 2008, CD4+ T-cell counts recovered, and he remains 
free of detectable replication-competent virus, in the absence of cART, over 8 years later 
[4]. More recently, two lymphoma patients in Boston received allogeneic transplants with 
CCR5wt/wt cells. After hematopoietic recovery and extensive monitoring on cART, during 
which time HIV-1 was undetectable by multiple ultrasensitive assays, both patients were 
removed from cART, but continued on immunosuppressive therapy [5]. Viral rebound was 
observed within 12–32 weeks, and drug-resistant plasma viremia was encountered following 
re-initiation of cART in one of the two patients, necessitating transition to a new cART 
regimen [6]. The findings in the Berlin and Boston patients strongly suggest that cART 
disruption while still immunosuppressed is associated with viral rebound and the potential 
for resistance.
We have developed a model of HSCT in the pigtailed macaque, M. nemestrina [7–9]. 
Recently, we adapted our system to model gene therapy-mediated cure/remission of HIV-1 
infection using the wealth of knowledge regarding SIV and SHIV infection in nonhuman 
primate species including M. nemestrina ([10–13]. In this study we asked whether the 
immune response to SHIV challenge in transplanted animals was comparable to that in 
untransplanted controls.
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This study was carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the Institutional Animal Care and Use Committees of the Fred Hutchinson 
Cancer Research Center and University of Washington.
Animals
Seven healthy male juvenile pigtailed macaques (M. nemestrina) were housed at the 
Washington National Primate Research Center. Animals Z09087, Z09106, and Z09192 
(Group I) and Z09144 and Z08214 (Group II) were challenged with 9500 TCID50 
SHIV-1157ipd3N4 intravenously, and initiated cART 6 months post-SHIV challenge as 
previously described [11]. Approximately 1 year following infection, CD34+ hematopoietic 
stem cells from Group II animals, which were collected prior to SHIV challenge and 
cryopreserved [14], were thawed and transduced with a BFP-expressing lentiviral vector. 
BFP fluorescence was not analyzed for the purposes of this study. Cells were infused into 
the autologous animal following administration of myeloablative total body irradiation 
(TBI), consistent with our established protocols [14]. Animals A11202 and A11205 (Group 
III) were transplanted with a non-optimized CCR5 targeting protocol that generated 
physiologically irrelevant to undetectable levels of CCR5 gene disruption. At 100 days post-
transplant, these animals were also challenged with SHIV-1157ipd3N4. Due to declining 
health as described below, these animals initiated cART roughly four months earlier than 
Groups I–II.
Please see Supplementary Methods and Materials for Further Information
Results
Development of cART resistance in post-transplant animals
The different experimental groups used in this study are outlined in Figure 1A. We 
compared three animals that were challenged with SHIV, but did not undergo transplant 
(“Group I: No transplant”), two animals that were transplanted subsequent to SHIV 
challenge (“Group II: SHIV-transplant”), and two animals that were challenged with SHIV 
post-transplant (PT; “Group III: transplant-SHIV”). All seven animals were challenged with 
9500 TCID50 of the CCR5-tropic env-SHIV, SHIV1157-ipd3N4 intravenously, and 
received a 3-drug cART regimen following SHIV challenge. As shown in Figures 1B–1C, 
Group I and II animals displayed ranges of peak viral load and viral set points that were 
consistent with previous observations made by our lab and others [11, 15, 16]. In all Group I 
and II animals, 3-drug cART initiated at 25 weeks durably suppressed plasma viremia, with 
occasional viral blips, to the limit of detection of our assay (30 copies/mL). Group II animals 
remained durably suppressed during hematopoietic stem cell transplant (Figure 1C). By 
contrast, Group III animals exhibited sustained peak viremia through 10 weeks, with 
associated thrombocytopenia and low hematocrit (Figure 1D and data not shown) 
necessitating an earlier initiation of cART (Groups I–II: week 25–27; Group III: week 9–
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10). Interestingly, neither Group III animal was effectively suppressed by cART; although 
plasma viremia declined, it remained 2–4 logs above the limit of detection (Figure 1D). 
These results suggest that immunosuppressed animals undergo a more severe course of 
acute infection relative to controls, including sustained viremia and resistance to a 
previously validated cART regimen [11].
Resistance mutations in SHIV-C map to cART target genes Pol and RT
We hypothesized that cART resistance in Group III animals could be due to development of 
cART resistance mutations. We therefore employed a deep sequencing approach to monitor 
viral evolution in these animals. Total RNA was isolated from plasma from Groups I, II, and 
III at multiple time points following SHIV challenge, then reverse transcribed, sequenced, 
and compared to sequence data from the SHIV inoculum. We focused on the SIV RT and IN 
coding regions, the two targets for cART components PMPA/FTC and raltegravir, 
respectively. In Group I and II animals, no resistance mutations were observed prior to 
cART (Supplementary Table 1), and the subsequently durable and sustained suppression in 
these animals is a strong indicator that no drug resistance mutations emerged (although this 
was not confirmed as viral loads became too low for deep sequencing). Consistent with our 
hypothesis, we detected multiple known drug resistance mutations in Group III animals 
following cART initiation (Supplementary Table 1 and Figure 2). Pol N155H, a raltegravir 
resistance mutation [17–19], was detected within 3–9 weeks of cART initiation in the Group 
III animals (Figure 2A). In A11202, this mutation had grown to saturation when the animal 
was necropsied 38 weeks post-SHIV challenge. A11205 was euthanized at 27 weeks post-
SHIV challenge due to persistent thrombocytopenia and anemia, at which point the N155H 
mutation constituted 71% of the total population of SHIV Pol sequences. As was observed 
with A11202, this mutation was also trending towards saturation. The PMPA resistance 
mutation, K65R in SIV RT [20–22], was also detected in animal A11202 within 15 weeks of 
cART initiation (Supplementary Table 1 and Figure 2B). Hence, selection of cART-resistant 
SHIV viruses appears to be facilitated in post-transplant animals.
Plasma cART levels in post-transplant animals are comparable to controls
The Group II and III transplanted animals received a myeloablative conditioning regimen 
consisting of 1020 cGy total body irradiation (TBI), a dose associated with damage to the 
gut [23, 24]. This may interfere with absorption and bioavailability of the orally dosed 
cART component, raltegravir, facilitating selection of drug-resistant viral variants. We 
therefore used mass spectrometry to test whether PT animals (Group III) had lower 
circulating levels of cART compared to animals that were transplant-naïve at the time of 
cART initiation (Groups I–II). We measured plasma levels of each drug 1–2 weeks and 13–
20 weeks following cART initiation (Supplementary Figure 1A). At 1–2 weeks post-cART, 
plasma levels of tenofovir ranged between 13.7 and 74.8 ng/mL in Groups I and II and 
between 19.2 and 37.3 ng/mL in Group III animals (Figure S1B). Similarly, plasma 
concentrations of FTC in Group III animals (83.5 ng/mL and 83.0 ng/mL) fell within the 
range of 29.0–212.0 ng/mL found in Group I–II animals (Figure S1C). Most importantly, the 
orally dosed component, raltegravir, was also comparable: Group III animals had 139.0 and 
771.0 ng/mL, both within the range of 32.6–1480 ng/mL in Groups I–II (Figure S1D). At 
13–20 weeks, cART levels in each animal generally varied by less than 3-fold from their 
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levels 1–2 weeks post-cART, with the exception of Group II animal Z09144, which 
displayed a drastic increase in plasma concentrations of tenofovir and FTC (Figure S1B). 
Although drug resistance mutations were detected in Group III at this time point (Figure 2), 
their plasma tenofovir and FTC concentrations were still within the range detected in Group 
I and II controls (Figure S1B–C), while plasma raltegravir concentrations were higher than 
those in Group I and II (Figure S1D). Thus, cART resistance mutations in PT animals are 
unlikely to have arisen as a result of decreased plasma bioavailability.
Infection of myeloid subsets in post-transplant animals is comparable to controls
We tested two additional models that could explain why the Group III animals developed 
cART-refractory plasma viremia. First, we reasoned that the combination of sustained peak 
plasma viremia (Figure 1) and low baseline CD4+ T-cell counts (Figure 3) could have 
facilitated infection of peripheral blood CD4+ myeloid cells, which could serve as drug 
sanctuaries [25–27]. No significant differences in average monocyte counts were found in 
any animal during the course of study except for an elevation in Group III animal A11202 
between 6 and 12 weeks post-SHIV challenge (Supplementary Figure 2A–C). However, the 
ratio of monocytes to CD4+ T-cells was significantly elevated in Group III animals relative 
to Group I and II controls prior to (p<0.001) and following (p = 0.003) SHIV challenge 
(Supplementary Figure 2D–F). To test the hypothesis that an elevated ratio of monocytes to 
CD4+ T-cells is associated with increased infection of monocytic and other myeloid subsets, 
we measured total SHIV DNA in peripheral lymphoid (CD3+) vs. myeloid (CD14+) cells 
following sequential magnetic bead-based sorting (Supplementary Figure 3). The SHIV viral 
DNA load in CD14+ cells, which on average contained less than 4% CD3+ contamination 
(Figure S3A), was comparable across all three groups of animals (Figure S3B), as was the 
viral DNA load in CD3+ cells (Figure S3C). Hence, the ratio of SHIV DNA+ CD14+ cells 
to SHIV DNA+ CD3+ cells was not significantly different (p=0.26) between Group III and 
Groups I–II (Figure S3D). These data suggest that SHIV DNA+ peripheral blood cells in PT 
animals were not overtly skewed towards a monocytic (CD14+) lineage.
Marked depletion of total and naïve CD4+ and naïve CD8+ T-cells is associated with drug 
resistance
Our second model to explain development of cART-resistant plasma viremia in post-
transplant animals was a loss of T- and B-cell-dependent restriction of infection during the 
acute phase, presumably due to insufficient hematopoietic reconstitution post-HSCT [28–
30]. Group I and II animals exhibited a mild decline of CD4+ cells during acute infection, 
with two animals in Groups I–II (Group I: Z09087, Group II: Z09144) declining further over 
6 months of infection prior to cART initiation. CD4+ T-cell counts gradually increased upon 
initiation of cART in all animals. Group II animals experienced a drop to <100 cells/μL 
following total body irradiation (TBI) during HSCT at week 53–56 (Figure 3A) and then 
gradually recovered. Group III (PT) animals had significantly lower pre-SHIV CD4+ T-cell 
counts than Groups I–II (p<0.0001; Figure 3B), decreased further in the first 9–10 weeks 
post-SHIV challenge, prior to initiation of cART (Figure 3C) but then recovered at a similar 
rate upon initiation of cART (Figure 3A). Analogous, but less striking trends were observed 
in peripheral blood CD8+ T-cell counts (Figure 3D–F). A marked depletion of peripheral 
blood naïve CD4+ and CD8+ T-cells was also noted in Group III prior to SHIV challenge 
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and cART (Figure S4B–S4C). Similar to total CD4+ T-cells, naïve subsets remained 
suppressed until initiation of cART in these animals. By contrast, central and effector 
memory T-cell counts in Group III animals were more difficult to distinguish from Group I–
II controls (Figure S4D–S4G). Depletion of CD4+ and CD4+CCR5+ T-cells in upper and 
lower GI was comparable across all Groups (Supplementary Figure S4H–S4K), as was 
depletion of peripheral blood CD4+CCR5+ cells (Figure S4A). Although we did not observe 
statistically significant differences in these counts, we did observe an unexpectedly rapid 
rebound of CD4+CCR5+ T-cells in each compartment following cART initiation in Group 
III. Taken together, these data indicate that post-transplant animals’ total and naive CD4+, 
and naïve CD8+ T-cell counts are suppressed due to TBI, remain suppressed during acute 
SHIV infection, and rebound following cART, despite persistent plasma viremia.
Drastic reduction in SHIV-specific antibody production in post-transplant animals
To assess B-cell function during acute SHIV infection in Groups I–III, we longitudinally 
measured production of anti-SHIV antibodies: those against SIVmac239, the backbone of 
the env-SHIV virus used (Figure 4A), and against a heterologous HIV envelope, SF162 
(Figure 4B). Anti-SHIV antibody production in Groups I and II was comparable: production 
was first detected within 5 weeks of SHIV challenge, increased to 4–5 logs prior to cART 
initiation, and decreased by approximately 1 log following cART (Figure 4A,B). In contrast, 
anti-SIV antibodies were very low in Group III animals: they were not detected in A11202 
until 25 weeks post-SHIV challenge (15 weeks post-cART), and remained 2–3 logs below 
Groups I and II. Anti-SIV antibodies were initially detected early in Group III animal 
A11205 but fluctuated above and below the limit of detection (Figure 4A). Anti-HIV Env 
antibodies were not detected in A11202 until week 25 post-infection, while levels in 
A11205 remained near the limit of detection throughout the course of study (Figure 4B). 
Importantly, CD20+ B-cell levels were roughly comparable in all three groups throughout 
the study, with the exception of the transient depletion observed in Group II following TBI, 
and a slight decrease in Group III animal A11202 prior to initiation of cART at week 10 
post-infection (Figure 4C). These results suggest that Group III animals lack an acute 
antibody response following SHIV challenge, which is independent of CD20+ B-cell levels.
Discussion
We demonstrate that post-transplant animals undergoing autologous HSCT-mediated gene 
therapy 100 days prior to SHIV challenge are subject to an aggressive acute phase of 
infection, rapid resistance to cART therapy, and poorer prognosis (Figures 1 and 2). Our 
data suggest that accrual of cART resistance mutations is neither a function of suboptimal 
cART bioavailability (Figure S1), nor of an augmented repertoire of infection-susceptible 
cells in peripheral blood (Figure S3). Rather, we observed decreased T-cell counts in post-
transplant animals prior to infection, which was further exacerbated during the initial phase 
of infection (Figure 3). Although B-cell counts in these animals were unchanged relative to 
the impact on T-cells, production of SHIV-specific antibodies was highly impaired (Figure 
4). These findings are most consistent with a model in which immune cell counts and 
functionality, drastically reduced following TBI, are only partially restored at the time of 
SHIV challenge. The impaired immune system appears to be unable to restrict infection 
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during the acute phase, resulting in sustained peak viremia, facilitating selection for drug-
resistant mutants upon cART initiation, and ultimately accelerating disease progression 
(Figure 5).
These data reinforce recent findings from our group and others [13, 31], that autologous 
HSCT, including myeloablative TBI, is safe and feasible in infected, stably suppressed 
animals (Figure 1B–C). Conversely, PT animals (Figure 1D) exhibited a more pathogenic 
course of infection following SHIV challenge, a finding that is relevant to clinical analytical 
treatment interruption (ATI) studies. Our data is consistent with recent findings from 
Henrich et al. [6], in which one of the two HIV+ Boston patients undergoing reduced-
intensity conditioning and allogeneic stem cell transplantation developed cART resistance 
following ATI. Importantly, the Boston patient’s resistance arose despite the fact that ATI 
was over two years removed from HSCT; the fact that this patient remained on 
immunosuppressive therapy suggests that our observations may extend far beyond acute 
(100 days) recovery post-HSCT. It remains to be determined what complicating factors may 
have also contributed to cART resistance in this patient, for example, cART adherence 
anomalies before or after HSCT, or ongoing immunosuppressive therapy and GVHD. In 
stark contrast, the Berlin patient ceased cART therapy concurrent with the first of two 
rounds of myeloablative conditioning, yet remains free of detectable replication-competent 
virus over 8 years later [4, 32]. We are currently investigating the contributions made by 
infusion of infection-resistant cells to better model the clinical course of the Berlin patient. 
In these experiments, animals undergoing a 200-day recovery post-transplant exhibit a more 
prototypical course of SHIV infection, as compared to Group III animals in the present study 
that recovered for 100 days (manuscripts in preparation). These findings suggest that the 
period between 100 and 200 days post-transplant is a critical recovery window, during 
which the host immune system recovers sufficiently to respond to SHIV challenge. Our 
ongoing de novo infection experiments, as well as experiments involving ATI in infected 
and cART-suppressed animals, now include a standard 200-day recovery post-transplant.
Myeloablative conditioning regimens such as TBI may augment replication-competent viral 
reservoirs in two ways. First, residual tissue damage following TBI may impair cART 
uptake. Our data suggest that plasma drug levels are comparable in post-transplant animals, 
relative to transplant-naïve controls (Figure S1). These data leave open the possibility that 
antiretroviral (ARV) uptake from plasma is impaired in select tissues, leading to 
establishment of novel drug sanctuaries and persistent SHIV replication. Second, TBI may 
also have accelerated seeding of infection in tissues such as the central nervous system 
(CNS), since TBI and associated inflammation are known to permeabilize the blood brain 
barrier (BBB; [33–35]). TBI-dependent permeabilization of the BBB could facilitate passage 
of replication-competent virus into the CNS. Following BBB repair, when cART delivery to 
the CNS may be impeded, this enhanced viral reservoir would represent a significant barrier 
to cART-mediated suppression [36]. Together, alterations in ARV drug biodistribution and 
tissue exposure to infectious virus following HSCT could explain why we observed rebound 
of peripheral blood CD4+ T-cells following cART initiation, despite incomplete suppression 
of plasma viremia. Despite normal plasma levels of ARVs and full protection of circulating 
CD4+ T-cells, cART-refractory and/or SHIV hyper-penetrant tissues may have represented 
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the source of high circulating levels of virus. We are currently mapping the animal-wide and 
cell type-specific biodistribution of ARVs, SHIV RNA, and SHIV DNA to identify 
anomalies in experimental groups such as post-transplant animals. Although techniques to 
measure intracellular cART concentrations on a per-cell basis are still in their infancy, we 
believe that understanding the relative distribution of virus and cART in our model will 
allow us to characterize the overlap between sites of active viral replication and drug 
exclusion. Such detailed mapping will allow for the detection of alterations in post-
transplant animals and HIV+ gene therapy patients.
CCR5-tropic SHIVs, as used in this study, manifest acute pathogenesis primarily in 
secondary lymphoid tissues like the GI tract rather than peripheral blood, due to the relative 
numbers of CD4+CCR5+ target cells in these compartments [16, 37–39]. Notably, B-cell 
defects have also been observed at these tissue sites [40–42]. We observed an unexpectedly 
dramatic loss of CD4+ T-cells in the peripheral blood in the post-transplant animals 
following SHIV challenge, which rebounded rapidly following initiation of cART (Figure 
3). Similar, less striking trends were observed in the GI tract (Figure S4). Paradoxically, 
rebound in CD4+CCR5+ counts following cART occurred despite ongoing viral replication 
in post-transplant animals. We have no evidence to suggest that these rebounding cells are 
refractory to SHIV infection. Rather, these results are consistent with our recent finding that 
HSCT-dependent mechanisms upregulate CCR5 expression on circulating T-cells [13]. We 
hypothesize that de novo expression of CCR5 at the surface of previously CD4+CCR5− cells 
replenishes the pool of infection-susceptible targets, generating target cells at a greater rate 
than they are eliminated by ongoing infection. The balance between generation and killing 
of CD4+CCR5+ cells is further complicated by the decrease in naïve T-cells we observe 
(Figure S4B–C), which may skew infection towards effector memory T-cells (Figure S4F–
G). We are currently investigating impairment of peripheral blood T-cell function in post-
transplant animals, and are also examining the role of other regulatory cells in the periphery, 
such as myeloid-derived suppressor cells [43, 44]. A better understanding of the effects of 
HSCT on CCR5 expression by CD4+ cells will be required in order to generate effective 
CCR5-based antiviral therapies.
Finally, our findings are consistent with recent work from Micci et al. [45] in which 
experimental CD4 depletion followed by SIVmac251 challenge resulted in sustained high 
plasma viremia. Interestingly, the authors observed massive inflammation and infection of 
myeloid subsets in their animals. We similarly postulate that myeloid subsets might be at 
increased susceptibility for infection in post-transplant animals. Although we did not 
observe a significant enrichment of SHIV DNA+ CD14+ cells either prior to or following 
initiation of cART (Figure S3), this analysis was limited to peripheral blood, whereas Micci 
et al. observed dramatic effects in lymph nodes, gut, and CNS. It will be intriguing to 
compare the effects of TBI, which our data and past work shows is broadly lymphotoxic 
[46], to targeted CD4 depletion. Comparing these two models may reveal TBI-sensitive 
cellular subsets in blood and tissue whose function is required for gene therapy-mediated 
protection during ATI.
To summarize, we observed that immune-compromised animals exhibited sustained peak 
plasma viremia following SHIV challenge and were at increased risk for development of 
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cART resistance mutations following cART initiation. These effects were associated with 
low levels of total and naïve CD4+ and naïve CD8+ T-cells, and deficiencies in the 
production of anti-SHIV antibodies. These results begin to shed light on the complex, 
multifactorial immune deficiency that exists following myeloablative HSCT, and underscore 
the need for exhaustive measurement of immune homeostasis in the context of gene therapy-
mediated HIV cure trials.
Supplementary Material
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Figure 1. cART-resistant SHIV plasma viremia is observed in post-transplant M. nemestrina
A) Longitudinal plasma viral loads were measured in 3 untransplanted animals (“No 
transplant”), 2 animals infected with SHIV and then transplanted (“SHIV-transplant”), and 
two animals transplanted and then infected with SHIV (“transplant-SHIV”). B–D) Viral 
loads over time in each of the three groups. Crosses represent necropsy for A11202 and 
A11205 (Group III).
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Figure 2. Detection of drug resistance mutations in SHIV integrase and reverse transcriptase in 
post-transplant animals
Total RNA was extracted from plasma from Post-transplant animals A11202 (solid lines) 
and A11205 (dotted lines) and subjected to Illumina MiSeq deep sequencing at SHIV 
integrase (A) and reverse transcriptase (B). Green lines represent plasma viral loads. Black 
boxes represent frequency of sequencing reads containing the indicated mutation. Arrows 
denote initiation of cART at 9–10 weeks post-challenge.
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Figure 3. Peripheral blood T-cell counts are suppressed prior to SHIV challenge in post-
transplant animals, but recover following initiation of cART
Flow cytometry was used to longitudinally measure T-cell counts in peripheral blood from 
no transplant (blue), SHIV-transplant (red), and transplant-SHIV (green) animals. Arrows 
indicate time of cART initiation and autologous transplant, where applicable, for each 
group. A) CD4+ T-cell counts/μL over the course of SHIV infection in each animal. B) 
Average CD4+ T-cell counts over 4–6 weeks prior to SHIV challenge. C) Average CD4+ T- 
cell counts over 9–10 weeks post-challenge, prior to Group III animals initiating cART. D) 
CD8+ T-cell counts/μL were measured longitudinally as in A). E) Average CD8+ T-cell 
counts over 4–6 weeks prior to SHIV challenge. F) Average CD8+ T- cell counts over 9–10 
weeks post-challenge, prior to Group III animals initiating cART. Error bars represent 
standard deviations between weekly measurements. Statistical significance between 
collective measurements from Groups I–II and Group III was measured by single-tailed 
Student’s t-test. ** represents p < 0.01, and **** represents p < 0.0001.
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Figure 4. Post-transplant animals display significant impairment in production of anti-SHIV 
antibodies, despite comparable CD20+ B-cell counts
ELISA was used to measure the serum titer of antibodies specific for SIVmac239 (A) or 
HIV-1 SF162 Env (B) from no transplant (blue), SHIV-transplant (red), and transplant-
SHIV (green) animals. Titer was calculated as the reciprocal of the highest serum dilution 
that resulted in an optical density reading greater than the average values obtained with 
negative macaque sera plus three standard deviations. C) CD20+ B-cell counts per μL in 
peripheral blood were measured by flow cytometry. Arrows indicate time of cART initiation 
and autologous transplant, where applicable, for each group.
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Figure 5. Model for cART resistance in post-transplant animals
Following SHIV challenge, healthy animals and post-transplant animals stochastically 
generate equivalent numbers of cART-resistant mutants (red). In healthy animals, T- and B-
cell responses and decreased viral fitness both restrict propagation of these mutants. In 
contrast, post-transplant animals’ impaired T- and B-cell repertoire limit viral restriction 
during the transition to set point viremia, increasing the likelihood that mutants will persist 
in sufficient numbers to undergo positive selection following initiation of cART.
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